Abstract 5069: Comprehensive mutational analysis of epidermal growth factor receptor, EML4-ALK, and KRAS identifies four distinct disease entity in never-smoker patients with non-small cell lung cancer

Abstract 4688: A relationship between environmental tobacco smoke (ETS) and epidermal growth factor receptor (EGFR) mutations in never smoker patients with non-small cell lung cancer

10.1158/1538-7445.am10-4688 ◽

2010 ◽

Author(s):

Young Joo Lee ◽

Byoung Chul Cho ◽

Hye Jin Choi ◽

Jin Gu Lee ◽

Joo-Hang Kim

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Tobacco Smoke ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Epidermal Growth ◽

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

Yearbook of Oncology ◽

10.1016/s1040-1741(08)79218-2 ◽

2008 ◽

Vol 2008 ◽

pp. 188-189

Author(s):

N.H. Hanna

Keyword(s):

Lung Cancer ◽

In Situ Hybridization ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Faculty Opinions recommendation of Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1090134.543345 ◽

2007 ◽

Author(s):

Sam Janes

Keyword(s):

Lung Cancer ◽

In Situ Hybridization ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non‐Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib

Case Medical Research ◽

10.31525/ct1-nct04099836 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Progressive Disease ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Egfr Mutant

Faculty Opinions recommendation of Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1018878.217464 ◽

2004 ◽

Author(s):

Joachim Herz

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Small Cell Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Activating Mutations ◽

Epidermal Growth

Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer

Clinical & Translational Oncology ◽

10.1007/s12094-021-02701-x ◽

2021 ◽

Author(s):

D. Geng ◽

Q. Guo ◽

S. Huang ◽

H. Zhang ◽

S. Guo ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Molecular Characteristics ◽

Small Cell Lung ◽

Epidermal Growth ◽

Exon 20 ◽

Insertion Mutations

P37.17 Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Non-small Cell Lung Cancer (NSCLC): A Global Meta-analysis

10.1016/j.jtho.2021.01.764 ◽

2021 ◽

Vol 16 (3) ◽

pp. S449

Author(s):

B. Melosky ◽

E. Laack ◽

K. Kambartel ◽

M. Häntschel ◽

M. Bennetts ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Small Cell Lung ◽

Epidermal Growth

143P Physician perceptions of barriers to epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC)

10.1016/s1556-0864(21)01985-7 ◽

2021 ◽

Vol 16 (4) ◽

pp. S775

Author(s):

J. Subramanian ◽

Y-L. Choi ◽

T-Y. Chou ◽

J. Gregg ◽

R. Hui ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Advanced Stage ◽

Small Cell Lung ◽

Physician Perceptions ◽

Epidermal Growth

173P Evaluating the content validity, clarity, and relevance of the PROMIS-physical function (PROMIS-PF)-8C and non-small cell lung cancer (NSCLC)-Symptom assessment questionnaire (NSCLC-SAQ) in adults with epidermal growth factor receptor (EGFR)-mutated NSCLC

10.1016/s1556-0864(21)02015-3 ◽

2021 ◽

Vol 16 (4) ◽

pp. S792

Author(s):

M.K. Horn ◽

K. Liu ◽

S.D. Mathias ◽

H.H. Colwell ◽

T. Li ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Symptom Assessment ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Egfr Mutated ◽

Assessment Questionnaire

135P The real-world use of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor mutated (EGFRm) advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC) patients

10.1016/s1556-0864(21)01977-8 ◽

2021 ◽

Vol 16 (4) ◽

pp. S770-S771

Author(s):

J. Subramanian ◽

Y-L. Choi ◽

T-Y. Chou ◽

J. Gregg ◽

R. Hui ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Advanced Stage ◽

Small Cell Lung ◽

Epidermal Growth ◽

Nsclc Patients